Presentations
American Society of Clinical Oncology (ASCO) Annual Meeting, May 2011
Phase 1 trial of VB-111, a tissue- and condition-specific dual action vascular disruptive and antiangiogenic agent, for treatment of patients with advanced metastatic cancer
American Society of Gene & Cell Therapy (ASGCT) 14th Annual Meeting, May 2011
Synergistic effect of a novel gene therapeutic agent, VB-111, with chemotherapy, for treatment of cancer
American Association for Cancer Research (AACR) 102nd Annual Meeting, April 2011
Antiangiogenic gene therapy with VB111 is active in glioblastoma xenografts
American Association for Cancer Research (AACR) 102nd Annual Meeting, April 2011
VB-111 a novel antiangiogenic vector and a promising treatment for metastatic cancer in combination with other anti-cancer drugs
The European League Against Rheumatism (EULAR) Congress, June 2010
Lecinoxoid in the treatment of experimental Rheumatoid Arthritis
Keystone Symposium on Bioactive Lipids: Biochemistry and Diseases, June 2010
A Lecinoxoid, an Oxidized Phospholipid Small Molecule, regulates inflammatory pathways
Society for Investigative Dermatology (SID) 70th Annual Meeting, May 2010
Lecinoxoid in the treatment of psoriasis
American Association for Cancer Research (AACR) 101st Annual Meeting, April 2010
A Phase 1 trial of VB-111, a tissue and condition specific vascular disruptive anti-angiogenic agent, based on novel Vascular Targeting System™, VTS™, for treatment of patients with advanced metastatic cancer
